Nature Communications (May 2023)

macroH2A2 antagonizes epigenetic programs of stemness in glioblastoma

  • Ana Nikolic,
  • Francesca Maule,
  • Anna Bobyn,
  • Katrina Ellestad,
  • Seungil Paik,
  • Sajid A. Marhon,
  • Parinaz Mehdipour,
  • Xueqing Lun,
  • Huey-Miin Chen,
  • Claire Mallard,
  • Alexander J. Hay,
  • Michael J. Johnston,
  • Christopher J. Gafuik,
  • Franz J. Zemp,
  • Yaoqing Shen,
  • Nicoletta Ninkovic,
  • Katalin Osz,
  • Elodie Labit,
  • N. Daniel Berger,
  • Duncan K. Brownsey,
  • John J. Kelly,
  • Jeff Biernaskie,
  • Peter B. Dirks,
  • Darren J. Derksen,
  • Steven J. M. Jones,
  • Donna L. Senger,
  • Jennifer A. Chan,
  • Douglas J. Mahoney,
  • Daniel D. De Carvalho,
  • Marco Gallo

DOI
https://doi.org/10.1038/s41467-023-38919-2
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 22

Abstract

Read online

Abstract Self-renewal is a crucial property of glioblastoma cells that is enabled by the choreographed functions of chromatin regulators and transcription factors. Identifying targetable epigenetic mechanisms of self-renewal could therefore represent an important step toward developing effective treatments for this universally lethal cancer. Here we uncover an epigenetic axis of self-renewal mediated by the histone variant macroH2A2. With omics and functional assays deploying patient-derived in vitro and in vivo models, we show that macroH2A2 shapes chromatin accessibility at enhancer elements to antagonize transcriptional programs of self-renewal. macroH2A2 also sensitizes cells to small molecule-mediated cell death via activation of a viral mimicry response. Consistent with these results, our analyses of clinical cohorts indicate that high transcriptional levels of this histone variant are associated with better prognosis of high-grade glioma patients. Our results reveal a targetable epigenetic mechanism of self-renewal controlled by macroH2A2 and suggest additional treatment approaches for glioblastoma patients.